Secretagogue

Growth hormone secretagogues commonly act at the growth hormone secretagogue receptor, also called the ghrelin receptor. That matters because ghrelin biology reaches beyond growth-hormone release into appetite, glucose handling, gut movement, and other hormone signals, which helps explain why this category can produce effects that look broader than “more GH” alone.

The word that tells you almost nothing

On a label or forum post, secretagogue can sound impressively specific. It is not. The word only tells you that something is meant to make a gland or cell secrete—release—something. It does not tell you what is being released. That is why the same word can describe diabetes medicines that push the pancreas to release insulin and also describe compounds that push the brain-pituitary system to release growth hormone.

A conductor, not a replacement player

Picture an orchestra where the musicians are already onstage, but quiet. A secretagogue is the conductor’s cue, not a new musician walking in with a violin. That is the key idea: a secretagogue tries to get your own body to release more of a signal it already makes, rather than supplying that signal directly.

That is why a growth hormone secretagogue is different from taking growth hormone itself. Compounds in that family act through the ghrelin receptor—the same receptor tied to the hunger hormone ghrelin—to increase growth-hormone release pulses. And it is why an insulin secretagogue like glipizide or repaglinide is different from injecting insulin: it pushes pancreatic beta cells to put out more insulin, especially around meals.

Why the same word can hide very different consequences

Once you see the conductor idea, the next surprise lands: two secretagogues can share the same label while behaving nothing alike in real life.

An insulin secretagogue can lower blood sugar, but the push can overshoot and cause hypoglycemia, especially with older drug classes like sulfonylureas. A growth hormone secretagogue may raise growth hormone pulses, but it can also affect appetite, glucose handling, water retention, or other hormones because the ghrelin system is tied to much more than growth alone. In older-adult studies of MK-677, for example, researchers saw higher growth-hormone output and more fat-free mass, but also increased appetite, mild edema, muscle pain, and small worsening in glucose control and insulin sensitivity.

That is the trap in the supplement world. “Secretagogue” sounds like a clean benefit word, but it is really a mechanism category. You still have to ask: secretagogue for what?

How to spot it in the wild

In research papers, you may see growth hormone secretagogue, GHS, ghrelin receptor agonist, or insulin secretagogue. On product pages, you may see fuzzier phrases like GH secretagogue, secretagogue peptides, or even secretagogue HGH, which is sloppy wording because the product is not HGH itself—it is marketed as something that may stimulate release.

Pronunciation helps when you hear it aloud: seh-KREE-tuh-gog or seh-KREE-tuh-gawg are both common English renderings.

One decision that actually helps

If you see secretagogue on a label, do not compare it as if it were the ingredient name. Make one move instead: find the target secretion. If the product cannot clearly tell you what it is trying to make your body release—insulin, growth hormone, stomach acid, something else—the category word is doing more marketing work than scientific work.